Dapasel Tablets 10 mg (Dapagliflozin Anhydrous Mixture)
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.
MFDS item code 202101089 · Approved 2021.02.04
This product's status changed to Approval withdrawn on 2025.08.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improves blood glucose control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone when meals and exercise are difficult. If blood sugar control is difficult with monotherapy, it can be combined with other diabetes medications such as metformin, sulfonylureas, insulin, or sitagliptin. This combination therapy is tailored based on each patient's blood sugar condition and aids effective blood sugar management. Therefore, this medication plays an important role in improving blood sugar control.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no previous history of diabetes drug treatment, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients who are allergic to the active ingredients or excipients. It should not be taken by patients with type 1 diabetes or diabetic ketoacidosis. As it contains anhydrous lactose, it should not be administered to patients with lactose intolerance or related genetic disorders. Patients undergoing renal dialysis should also not use this medication. Patients with reduced fluid volume or impaired renal function should use this medication cautiously, and fluid status and kidney function should be carefully monitored before and during administration. As this medication can lower blood pressure, elderly patients with a history of hypotension or those taking diuretics should be cautious. Caution is also needed in patients allergic to Tartrazine (Yellow No. 4) and Yellow No. 5. During treatment, genital infections and urinary tract infections may occur; if symptoms of infection arise, immediate consultation with healthcare providers is necessary. Hyposensitivity symptoms may occur, so dosage adjustment may be necessary when used in combination with insulin or sulfonylureas. Monitor for dehydration or hypotension symptoms due to fluid loss; if symptoms are severe, consider stopping the medication. There is a risk of developing diabetic ketoacidosis, so immediate testing and treatment are needed if related symptoms (nausea, vomiting, abdominal pain, difficulty breathing, etc.) appear. Reduced kidney function may diminish the effectiveness of this medication and pose a risk of worsening renal function, so caution is required. This medication is not recommended for patients with severe liver dysfunction. Pregnant or breastfeeding women should avoid using this medication. There is no specific antidote for overdose, so appropriate treatment should be provided based on symptoms. This medication does not significantly affect the ability to drive or operate machinery; however, caution should be exercised due to the risk of hypoglycemia. The safety and efficacy of this medication in children have not been established. When taken with antihypertensive agents or diuretics, the risk of dehydration or hypotension may increase; consult with healthcare providers. It may affect blood lithium levels, so patients on lithium should regularly check their blood levels. Weight loss may occur during treatment with this medication. Diabetic patients should be vigilant about foot care, as there may be an increased risk of lower limb amputation. Immediately inform healthcare providers if there is pain, swelling, or fever around the perineum.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, reduced fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, initial treatment decreased renal creatinine clearance, dyslipidemia, initial treatment increased serum creatinine, elevated blood urea, weight loss, rash, angioedema, urosepticemia, pyelonephritis, acute kidney injury, renal dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is best to store the medication at a temperature between 1 and 30 degrees Celsius, which is typical room temperature, and not in excessively hot or cold places.
Yellow-brown, biconvex, rhomboid film-coated tablets
28 tablets/box [14 tablets/PTP X 2, 7 tablets/PTP X 4]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.